Drugs / HRS-5041
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07115446 | Aug 2025 → Dec 2027 expected | prostate cancer | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 1 | NCT07014488 | Jun → Aug 2025 | prostate cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06830850 | Jun 2025 → Dec 2026 expected | castration-resistant prostate carcinoma | Atridia Pty Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06559007 | Sep 2024 → Jan 2025 | prostate cancer | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05942001 | Aug 2023 → Sep 2026 overdue | castration-resistant prostate carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06568094 | Sep 2024 → Dec 2026 expected | prostate cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06738745 | Dec 2024 → Jan 2027 expected | metastatic prostate carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT07407283 Background | Apr 2026 → Nov 2027 expected | prostate cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-5041 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07115446 ↗ |
| Modality | Other / unclassified | “HRS-5041 is a Proteolysis Targeting Chimeras (PROTAC)” NCT07115446 ↗ |
| Route | Oral | “HRS-5041 was given oral administration” NCT05942001 ↗ |
| Target | AR | “targeting androgen receptors” NCT07115446 ↗ |